Avenge Bio Announces Peer-Reviewed Publication on Preclinical Proof-of-Concept for LOCOcyte™ Platform Technology in Malignant Mesothelioma
/PRNewswire/ -- Avenge Bio, Inc., ("Avenge" or the "Company") a biotechnology company developing the LOCOcyte™ immunotherapy platform for the precision...